AMLX

Amylyx Pharmaceuticals, Inc.

31.64 USD

Last updated Sep 12, 04:50 UTC

Yesterday HIGH

$32.57

Yesterday LOW

$31.44

52w HIGH

$41.13

52w LOW

$10.07

EPS

-0.39

PE

-81.13

Next Earnings

Nov 5, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Amylyx Pharmaceuticals, Inc. stock is up 40.75% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 September’s closed higher than August. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

21 Aug 18:29	18 Sep, 2026	40.00	CALL	168	4182
21 Aug 18:35	18 Sep, 2026	40.00	CALL	150	4182
21 Aug 19:37	21 Aug, 2026	33.00	CALL	158	208
26 Aug 15:05	16 Oct, 2026	35.00	PUT	250	2052
26 Aug 19:32	17 Dec, 2027	50.00	CALL	55	81
27 Aug 14:02	18 Dec, 2026	12.00	CALL	12	48
28 Aug 16:07	20 Nov, 2026	30.00	PUT	150	132
28 Aug 18:07	17 Dec, 2027	20.00	CALL	449	463
09 Sep 19:51	17 Dec, 2027	35.00	PUT	30	632
09 Sep 19:53	18 Sep, 2026	35.00	PUT	100	523

Advanced Data Unlock

Avi Kapoor

Tue Aug 18, 2026

Why Flexsteel Industries Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

Flexsteel Industries Inc (FLXS) reported better-than-expected Q4 results, with shares jumping 9% in pre-market trading. Other gainers include PFSA, EJH, XOS, WETO, SGLY, VOGX, WFF, AMLX, and ENRD. Losers include SNYR, XPON, NOMA, BTAI, and YOUL.
Benzinga Insights

Mon Aug 17, 2026

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.
Adam Eckert

Mon Aug 17, 2026

Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why

Amylyx Pharmaceuticals shares are trading higher Monday after the company scheduled a Phase 3 trial results readout for this week.
Benzinga Newsdesk

Mon Aug 17, 2026

Amylyx Pharmaceuticals shares are trading higher after the company announced it will reveal its topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026.
Benzinga Newsdesk

Mon Aug 17, 2026

Amylyx Pharmaceuticals To Announce Phase 3 LUCIDITY Trial Topline Results For Avexitide In Post-Bariatric Hypoglycemia On August 18 At 8:00 a.m. ET

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18,
Benzinga Newsdesk

Mon Aug 17, 2026

Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.
Benzinga Newsdesk

Thu Aug 6, 2026

Amylyx Pharma shares are trading higher despite reporting weak Q2 results. The market may be looking ahead to a pivotal Phase 3 LUCIDITY trial data readout, with strong cash reserves and clear regulatory strategy reducing risk and fueling optimism.
Benzinga Newsdesk

Thu Aug 6, 2026

RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028

Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 15.22 percent increase over losses of $(0.46) per share from
Benzinga Newsdesk

Mon Aug 3, 2026

Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26

Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $20 to $26.
Benzinga Newsdesk

Mon Jul 20, 2026

Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $24

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $21 to $24.

Guggenheim

Thu Aug 27, 15:43

buy

confirm
Mizuho

Wed Aug 19, 19:41

buy

confirm
Guggenheim

Wed Aug 19, 15:28

buy

confirm
Baird

Wed Aug 19, 13:02

buy

confirm
HC Wainwright & Co.

Tue Aug 18, 19:36

buy

confirm
Mizuho

Mon Aug 17, 13:26

buy

confirm

Advanced Data Unlock

Karen Firestone, Insider

Mon Aug 31, 2026

AMLX Recent Insider Trades and Stock Chart

50,000 shares converted
JAMES FRATES, Chief Financial Officer

Tue Aug 18, 2026

AMLX Recent Insider Trades and Stock Chart

22,807 shares awarded
Justin Klee, Co-Chief Executive Officer

Tue Aug 18, 2026

AMLX Recent Insider Trades and Stock Chart

60,039 shares awarded
Gina Mazzariello, Chief Legal Officer

Tue Aug 18, 2026

AMLX Recent Insider Trades and Stock Chart

21,284 shares awarded
Camille Bedrosian, Chief Medical Officer

Tue Aug 18, 2026

AMLX Recent Insider Trades and Stock Chart

22,807 shares awarded
Joshua B Cohen, Co-Chief Executive Officer

Tue Aug 18, 2026

AMLX Recent Insider Trades and Stock Chart

60,039 shares awarded